Table 2.
Association of SUA levels with risk of MAFLD
| Male | Serum uric acid [OR (95%CI)] | P for trend | Continuousa | ||||
|---|---|---|---|---|---|---|---|
| Group 1 (< 4.0 mg/dL) | Group 2 (4.0–4.9 mg/dL) | Group 3 (5.0–5.9 mg/dL) | Group 4 (6.0–6.9 mg/dL) | Group 5 (≥ 7.0 mg/dL) | |||
| Model 1 | 1 (ref) | 1.53 (1.21–1.93) | 2.69 (2.06–3.52) | 4.56 (3.58–5.82) | 6.72 (5.19–8.70) | < 0.001 | 1.57 (1.48–1.66) |
| Model 2 | 1 (ref) | 1.12 (0.86–1.45) | 1.44 (1.11–1.86) | 2.03 (1.60–2.59) | 2.46 (1.86–3.26) | < 0.001 | 1.27 (1.20–1.35) |
| Model 3 | 1 (ref) | 1.10 (0.84–1.45) | 1.33 (1.01–1.75) | 1.65 (1.27–2.14) | 1.72 (1.25–2.37) | < 0.001 | 1.17 (1.09–1.24) |
Model 1 was adjusted for demographic factors: age, sex, race/ethnicity, marital status, education level, and occupation type
Model 2 was adjusted for model 1 plus lifestyle factors: smoking status, alcohol consumption, physical exercise, BMI, and eGFR
Model 3 was further adjusted for model 2 plus biochemistry factors: triglyceride, total cholesterol, fasting glucose, CRP, and ALT
aOR for 1 mg/dL SUA increase